A 8-week, Multi Center(10),Single Arm, Open-labeled Prospective Study of Valsartan 160 mg in 200 Mild to Moderate Chinese Hypertension Patients Forced Titrated From 2-week Therapy of Valsartan 80 mg.
Phase of Trial: Phase IV
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2012 New trial record